Nanoparticle transport across the blood brain barrier

Andreas M. Grabrucker; Barbara Ruozi; Daniela Belletti; Francesca Pederzoli; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi

doi:10.1080/21688370.2016.1153568

Nanoparticle transport across the blood brain barrier

Andreas M. Grabrucker
, Barbara Ruozi
, Daniela Belletti
, Francesca Pederzoli
, Flavio Forni
, Maria Angela Vandelli
, Giovanni Tosi

Ulm University
University of Modena and Reggio Emilia

Research output: Contribution to journal › Review article › peer-review

Abstract

ABSTRACT: While the role of the blood-brain barrier (BBB) is increasingly recognized in the (development of treatments targeting neurodegenerative disorders, to date, few strategies exist that enable drug delivery of non-BBB crossing molecules directly to their site of action, the brain. However, the recent advent of Nanomedicines may provide a potent tool to implement CNS targeted delivery of active compounds. Approaches for BBB crossing are deeply investigated in relation to the pathology: among the main important diseases of the CNS, this review focuses on the application of nanomedicines to neurodegenerative disorders (Alzheimer, Parkinson and Huntington's Disease) and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.

Original language	English
Journal	Tissue Barriers
Volume	4
Issue number	1
DOIs	https://doi.org/10.1080/21688370.2016.1153568
Publication status	Published - 2 Jan 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BBB
drug delivery
drug targeting
liposome
nanocarrier
nanoparticle

Access to Document

10.1080/21688370.2016.1153568

Cite this

@article{979b1fe3736748069f75eb5f5c5adefe,

title = "Nanoparticle transport across the blood brain barrier",

abstract = "ABSTRACT: While the role of the blood-brain barrier (BBB) is increasingly recognized in the (development of treatments targeting neurodegenerative disorders, to date, few strategies exist that enable drug delivery of non-BBB crossing molecules directly to their site of action, the brain. However, the recent advent of Nanomedicines may provide a potent tool to implement CNS targeted delivery of active compounds. Approaches for BBB crossing are deeply investigated in relation to the pathology: among the main important diseases of the CNS, this review focuses on the application of nanomedicines to neurodegenerative disorders (Alzheimer, Parkinson and Huntington's Disease) and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.",

keywords = "BBB, drug delivery, drug targeting, liposome, nanocarrier, nanoparticle",

author = "Grabrucker, \{Andreas M.\} and Barbara Ruozi and Daniela Belletti and Francesca Pederzoli and Flavio Forni and Vandelli, \{Maria Angela\} and Giovanni Tosi",

note = "Publisher Copyright: {\textcopyright} 2016 Taylor \& Francis Group, LLC.",

year = "2016",

month = jan,

day = "2",

doi = "10.1080/21688370.2016.1153568",

language = "English",

volume = "4",

journal = "Tissue Barriers",

issn = "2168-8362",

number = "1",

}

TY - JOUR

T1 - Nanoparticle transport across the blood brain barrier

AU - Grabrucker, Andreas M.

AU - Ruozi, Barbara

AU - Belletti, Daniela

AU - Pederzoli, Francesca

AU - Forni, Flavio

AU - Vandelli, Maria Angela

AU - Tosi, Giovanni

PY - 2016/1/2

Y1 - 2016/1/2

N2 - ABSTRACT: While the role of the blood-brain barrier (BBB) is increasingly recognized in the (development of treatments targeting neurodegenerative disorders, to date, few strategies exist that enable drug delivery of non-BBB crossing molecules directly to their site of action, the brain. However, the recent advent of Nanomedicines may provide a potent tool to implement CNS targeted delivery of active compounds. Approaches for BBB crossing are deeply investigated in relation to the pathology: among the main important diseases of the CNS, this review focuses on the application of nanomedicines to neurodegenerative disorders (Alzheimer, Parkinson and Huntington's Disease) and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.

AB - ABSTRACT: While the role of the blood-brain barrier (BBB) is increasingly recognized in the (development of treatments targeting neurodegenerative disorders, to date, few strategies exist that enable drug delivery of non-BBB crossing molecules directly to their site of action, the brain. However, the recent advent of Nanomedicines may provide a potent tool to implement CNS targeted delivery of active compounds. Approaches for BBB crossing are deeply investigated in relation to the pathology: among the main important diseases of the CNS, this review focuses on the application of nanomedicines to neurodegenerative disorders (Alzheimer, Parkinson and Huntington's Disease) and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.

KW - BBB

KW - drug delivery

KW - drug targeting

KW - liposome

KW - nanocarrier

KW - nanoparticle

UR - https://www.scopus.com/pages/publications/84981214261

U2 - 10.1080/21688370.2016.1153568

DO - 10.1080/21688370.2016.1153568

M3 - Review article

C2 - 27141426

AN - SCOPUS:84981214261

SN - 2168-8362

VL - 4

JO - Tissue Barriers

JF - Tissue Barriers

IS - 1

ER -

Nanoparticle transport across the blood brain barrier

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this